Compare BAH & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAH | TGTX |
|---|---|---|
| Founded | 1914 | 1993 |
| Country | United States | United States |
| Employees | 31500 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 8.5B |
| IPO Year | 2010 | 2008 |
| Metric | BAH | TGTX |
|---|---|---|
| Price | $81.48 | $63.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $89.46 | $69.43 |
| AVG Volume (30 Days) | ★ 2.0M | 1.9M |
| Earning Date | 10-23-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | ★ 3.13 | 0.52 |
| Revenue | ★ $11,217,000,000.00 | $2,785,000.00 |
| Revenue This Year | $1.37 | $61.95 |
| Revenue Next Year | $4.61 | $35.55 |
| P/E Ratio | ★ $26.40 | $124.71 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $59.50 | $26.76 |
| 52 Week High | $109.10 | $68.03 |
| Indicator | BAH | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 57.99 |
| Support Level | $74.35 | $52.12 |
| Resistance Level | $81.76 | $68.03 |
| Average True Range (ATR) | 2.91 | 3.49 |
| MACD | -1.00 | 0.09 |
| Stochastic Oscillator | 0.39 | 67.11 |
Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace. The domains includes Consulting Services- Delivering strategic, operational, and management consulting to transform organizations; Advanced Tech- artificial intelligence, cloud integration, and data platforms. Cybersecurity that protects critical national infrastructure, military networks, and sensitive government systems and Engineering Solutions providing mission-critical technical design and hardware integration.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.